Home
Corporate
News
Investors
Technology
Patient Resources
Commercial
Contact Us
Click here for details of Bradmer's
Phase III Trial for GBM Patients
Bradmer Announces 2008 Second Quarter Operational And Financial Results
Bradmer Initiates Enrollment In Phase III GLASS-ART Trial In Primary Glioblastoma Multiforme
Bradmer Reports Progression Free Survival Data From Previous Phase II Glioblastoma Multiforme Trials
- PFS data from Neuradiab™ compares favorably to data from other technologies -
Bradmer Receives FDA Approval To Proceed With Phase III Clinical Trial
Bradmer Announces 2008 First Quarter Operational and Financial Results
Bradmer Appoints Robert Tessarolo To Board Of Directors
Bradmer Announces Phase II Results Published In Newly Diagnosed Glioblastoma Which Demonstrate Improved Survival And Support Upcoming Phase III Study
Bradmer Announces Additions To Scientific Advisory Board
Molecular Target of Bradmer's Neuradiab Further Validated by Independent Findings
Learn More
Toronto Stock Exchange: BMR
Per share amounts in Canadian Dollars
Learn More
© 2005 - 2008 Bradmer Pharmaceuticals
Forward-Looking Statements
|
Terms and Conditions of Use
